Your browser doesn't support javascript.
loading
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Dent, S; Brezden-Masley, C; Clarke, B; Davis, MK; Jassal, DS; Johnson, C; Lemieux, J; Paterson, I; Sebag, IA; Simmons, C; Sulpher, J; Thain, K; Thavendiranathan, P; Wentzell, JR; Wurtele, N; Côté, MA; Fine, NM; Haddad, H; Hayley, BD; Hopkins, S; Joy, AA; Rayson, D; Stadnick, E; Straatman, L; Virani, SA.
Affiliation
  • Dent, S; vc. CA
  • Brezden-Masley, C; Canadian Cardiovascular Society. CA
  • Clarke, B; Canadian Cardiovascular Society. CA
  • Davis, MK; Canadian Cardiovascular Society. CA
  • Jassal, DS; Canadian Cardiovascular Society. CA
  • Johnson, C; Canadian Cardiovascular Society. CA
  • Lemieux, J; Canadian Cardiovascular Society. CA
  • Paterson, I; Canadian Cardiovascular Society. CA
  • Sebag, IA; Canadian Cardiovascular Society. CA
  • Simmons, C; Canadian Cardiovascular Society. CA
  • Sulpher, J; Canadian Cardiovascular Society. CA
  • Thain, K; Canadian Cardiovascular Society. CA
  • Thavendiranathan, P; Canadian Cardiovascular Society. CA
  • Wentzell, JR; Canadian Cardiovascular Society. CA
  • Wurtele, N; Canadian Cardiovascular Society. CA
  • Côté, MA; Canadian Cardiovascular Society. CA
  • Fine, NM; Canadian Cardiovascular Society. CA
  • Haddad, H; Canadian Cardiovascular Society. CA
  • Hayley, BD; Canadian Cardiovascular Society. CA
  • Hopkins, S; Canadian Cardiovascular Society. CA
  • Joy, AA; Canadian Cardiovascular Society. CA
  • Rayson, D; Canadian Cardiovascular Society. CA
  • Stadnick, E; Canadian Cardiovascular Society. CA
  • Straatman, L; Canadian Cardiovascular Society. CA
  • Virani, SA; Canadian Cardiovascular Society. CA
Can. j. cardiol ; 32(7): 831-841, jul. 2016.
Article in English | BIGG - GRADE guidelines | ID: biblio-966080
Responsible library: BR1.1
ABSTRACT
Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This guideline, authored by a pan-Canadian expert group of health care providers and commissioned by the Canadian Cardiovascular Society, is intended to guide the care of cancer patients with established cardiovascular disease or those at risk of experiencing toxicities related to cancer treatment. It includes recommendations and important management considerations with a focus on 4 main areas identification of the high-risk population for cardiotoxicity, detection and prevention of cardiotoxicity, treatment of cardiotoxicity, and a multidisciplinary approach to cardio-oncology. All recommendations align with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Key recommendations for which the panel provides a strong level of evidence include (1) that routine evaluation of traditional cardiovascular risk factors and optimal treatment of preexisting cardiovascular disease be performed in all patients before, during, and after receiving cancer therapy; (2) that initiation, maintenance, and/or augmentation of antihypertensive therapy be instituted per the Canadian Hypertension Educational Program guidelines for patients with preexisting hypertension or for those who experience hypertension related to cancer therapy; and (3) that investigation and management follow current Canadian Cardiovascular Society heart failure guidelines for cancer patients who develop clinical heart failure or an asymptomatic decline in left ventricular ejection fraction during or after cancer treatment. This guideline provides guidance to clinicians on contemporary best practices for the cardiovascular care of cancer patients.
Subject(s)
Full text: Available Collection: Tematic databases Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Target 3.4: Reduce premature mortality due to noncommunicable diseases / Arterial Hypertension / Cardiovascular Disease / Other circulatory Diseases Database: BIGG - GRADE guidelines Main subject: Cardiotoxicity / Neoplasms / Antineoplastic Agents Type of study: Diagnostic study / Etiology study / Practice guideline / Prognostic study / Risk factors / Screening study Language: English Journal: Can. j. cardiol Year: 2016 Document type: Article Institution/Affiliation country: Canadian Cardiovascular Society/CA / vc/CA
Full text: Available Collection: Tematic databases Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Target 3.4: Reduce premature mortality due to noncommunicable diseases / Arterial Hypertension / Cardiovascular Disease / Other circulatory Diseases Database: BIGG - GRADE guidelines Main subject: Cardiotoxicity / Neoplasms / Antineoplastic Agents Type of study: Diagnostic study / Etiology study / Practice guideline / Prognostic study / Risk factors / Screening study Language: English Journal: Can. j. cardiol Year: 2016 Document type: Article Institution/Affiliation country: Canadian Cardiovascular Society/CA / vc/CA
...